# The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production

> **NCT03141827** · PHASE2,PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 9 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Insulin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03141827
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-14
- **Primary completion:** 2017-02-15
- **Final completion:** 2017-04-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03141827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03141827, "The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03141827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*